



Canadian Headache Society
Att. Dr Farnaz Amoozegar
South Health Campus
Rm 480043, 4th Floor
4448 Front Street S.E.
Calgary, Alberta, T3M 1M4
Fax: 403-956-2992

June 1st, 2021

To whom it may concern,

It has come to the attention of the members of the Canadian Headache Society that some insurance companies are refusing to cover the combination of Botox and a CGRP monoclonal antibody (BTX + CGRP MAB). Currently available CGRP monoclonal antibodies are erenumab (Aimovig) and galcanezumab (Emgality), Fremanezumab (Ajovy) and eptinezumab (Viyepti). All CGRP antibodies have shown effectiveness and safety in robust randomized-controlled trials(1).

This barrier to medical care is unwarranted, as there is no medical reason to deprive patients of this therapeutic combination. We have heard multiple clinicians voicing concerns for their patient's health as they are forced to choose between two drugs that had both significantly contributed to an improvement in their health, ability to function and quality of life.

Combining medications with different mechanisms to optimize the treatment of a disease is very common in medicine. Epilepsy, hypertension, diabetes and cancer are all treated with multiple combinations of drugs, some of them quite expensive (2-4). Chronic migraine is an underdiagnosed and undertreated condition that may lead to significant disability and require polytherapy.

There are scientific arguments supporting the BTX + CGRP MAB combination. Indeed, Botox does inhibit the release of CGRP, but other mechanisms could make them complementary:

1. Botox inhibits the release of CGRP from C fibers
2. Antibodies (data available on fremanezumab) block CGRP mostly on A-delta fibers (5)
3. Botox also inhibits the release of other peptides and activity of channels playing a role in neurogenic inflammation (6, 7)
4. Botox is injected locally, CGRP monoclonal antibodies act more diffusely

There is a strong clinical impression from many experts around the world that some patients with chronic migraine who get a partial benefit from Botox are further improved by the addition of a CGRP monoclonal antibody. In the PREEMPT trials, patients improved on a mean of 8 days per month from a baseline of 20 days (8). That means that a patient with a baseline of 22 days per month treated with Botox with a 50% response (reaching a frequency of 11 days per month) would still qualify for a CGRP MAB (8 days per month). Also, the clinically meaningful response in chronic migraine is usually considered to be 30%, since these patients may be severely disabled (9, 10).

Real world evidence on the BTX + CGRP MAB combination has been accumulating. Multiple series now demonstrate a clinically significant benefit, allowing severely affected patients to improve their health, ability to function and quality of life(11-13). Recent abstracts are also available (see references).

The headache frequency is not the only outcome to take into account when treating chronic migraine (14). Interictal symptoms such as fatigue and neck pain, co-morbid mood disorders, neck pain, effectiveness of acute treatments, pain intensity and resistance to the trigger load are all important aspects of the patient's quality of life.

There is no medical risk (theoretical or observed in the clinic until now) to combine Botox and CGRP MABs. Many currently used oral migraine preventives have significant side effects and long term toxicities that are more harmful to patients than Botox and probably CGRP MABs (15).

The financial argument to deprive patients of access to care is not sufficient. A combination of Emgality with Botox would cost \$10 876 per year (12 X 623 + 4 x 850). Other medications in neurology are more costly and not necessarily more cost-effective than a MAB/Botox combination. For example, the cost of natalizumab for multiple sclerosis is \$40 000 per year (16). We are concerned that the stigma on migraine may lead to a different perception of this disease despite clear data on costs and burden (17-20).

In summary, the Canadian Headache Society supports the combination of Botox and CGRP antibodies in selected patients. Responders to this combination should be able to get coverage from their insurance companies.

We invite insurance companies, employers, and any other interested stakeholders to contact us to discuss this important clinical situation. The Canadian Headache Society is committed to the improvement of patient care and research in the headache field.

Sincerely,

Elizabeth Leroux



Dr Elizabeth Leroux, MD, FRCPC
President, Canadian Headache Society

The 2021 Board of the Canadian Headache Society
Dr Elizabeth Leroux (President), Montreal
Dr Farnaz Amoozegar (Treasurer, CCNS course), Calgary
Dr Suzanne Christie (Vice-president, Guideline committee), Ottawa
Dr Paul Cooper (Secretary), London
Dr Rose Giammarco, Hamilton
Dr Wasif Hussain, Edmonton
Dr Christine Lay, Toronto
Dr Will Kingston, Toronto
Dr Michael Knash, Edmonton
Dr Marissa Lagman, Toronto
Dr Werner Becker, Calgary

References

1. Tepper SJ. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. *Headache*. 2018;58 Suppl 3:238-75.
2. Chatterjee N, Bivona TG. Polytherapy and Targeted Cancer Drug Resistance. *Trends Cancer*. 2019;5(3):170-82.
3. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2018;71(19):e127-e248.
4. Nair DR. Management of Drug-Resistant Epilepsy. *Continuum (Minneapolis, Minn)*. 2016;22(1 Epilepsy):157-72.
5. Melo-Carrillo A, Strassman AM, Nir R-R, Schain A, Nosedá R, Stratton J, et al. Fremanezumab - a humanized monoclonal anti-CGRP antibody — inhibits thinly myelinated (A δ) but not unmyelinated (C) meningeal nociceptors. *The Journal of Neuroscience*. 2017;37:2211-17.
6. Zhang X, Strassman AM, Novack V, Brin MF, Burstein R. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle? *Cephalalgia*. 2016;36(9):875-86.
7. Favre-Guilmarc C, Auguet M, Chabrier PE. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. *European journal of pharmacology*. 2009;617(1-3):48-53.
8. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. *Headache*. 2010;50(6):921-36.
9. Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK, et al. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. *The journal of pain : official journal of the American Pain Society*. 2015;16(2):164-75.
10. Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. *Cephalalgia*. 2011;31(7):837-50.
11. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigárova L, et al. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. *Pain Ther*. 2021.
12. Cohen F, Armand C, Lipton RB, Vollbracht S. Efficacy and Tolerability of Calcitonin Gene-Related Peptide Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine. *Pain Med*. 2021.
13. Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis. *J Pain Palliat Care Pharmacother*. 2021;35(1):1-6.
14. Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people's life. *J Headache Pain*. 2019;20(1):41.
15. VanderPluym J, Evans RW, Starling AJ. Long-Term Use and Safety of Migraine Preventive Medications. *Headache*. 2016;56(8):1335-43.
16. Hartung DM. Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA. *Neurotherapeutics : the journal of the American Society for Experimental Neurotherapeutics*. 2017;14(4):1018-26.
17. Young WB, Park JE, Tian IX, Kempner J. The stigma of migraine. *PLoS One*. 2013;8(1):e54074.
18. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*. 2019;18(5):459-80.
19. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. *J Headache Pain*. 2016;17(1):104.
20. Lanteri-Minet M. Economic burden and costs of chronic migraine. *Curr Pain Headache Rep*. 2014;18(1):385.
21. Gottschalk PC. Anti-CGRP class reduces migraine burden regardless of concomitant therapies in US clinical practice[poster]. Annual Meeting of the American Academy of Neurology; 2020.
22. Suri H. Combination of erenumab and onabotulinum toxin A is a safe and effective treatment for chronic migraine [poster]. Annual Meeting of the American Headache Society; 2020 June 13, 2020.